←Crohn Disease
Study register · detail RCT (double-blind, placebo-controlled) · Crohn Disease · 2021

Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial

Naftali et al. ·Journal of Crohn's and Colitis Impact 0.9
Mixed GRADE Moderate 77 citations
Samplen = 56 Pat.
Duration8 weeks
ControlPlacebo oil, oral, 8 weeks
EndpointCDAI
Blindingdoppelblind
DesignRCT (double-blind, placebo-controlled)
Cannabinoidkombination
THC:CBD4:1
Routeoral
Key finding

CBD-rich cannabis led to significant clinical improvement (CDAI reduction) and improved quality of life, but no significant improvements in endoscopic scores or inflammation markers.

Summary

Naftali et al. 2021 — double-blind RCT, n=56 Crohn's disease patients (30 cannabis, 26 placebo); CBD-rich cannabis oil (160/40 mg/ml CBD/THC) vs. placebo over 8 weeks. CDAI reduction significant in cannabis group (median 282→166) vs. placebo (264→237), p<0.05. Quality-of-life score improved (74→91 cannabis vs. 74→75 placebo, p=0.004). NO significant change in endoscopic score (SES-CD) or inflammation markers (CRP, calprotectin, p=0.75). Clinical remission without endoscopic or inflammatory improvement; well tolerated.

P
PopulationAdults with active Crohn's disease (CDAI ≥220), n=56, age 34,5 ± 11 years
I
InterventionOral cannabis oil 160/40 mg/ml CBD/THC, 8 weeks
C
ControlPlacebo oil, oral, 8 weeks
O
OutcomeCDAI reduction significant (p<0,05) in cannabis vs. placebo group; QOL improvement (p=0,004); SES-CD without significant change (p=0,75); CRP and calprotectin unchanged
Confidence in the evidence
Moderate

The third of four GRADE levels, the effect estimate is probably reliable.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding Double-blind
Effect size Mixed
Citations / year ★★★★★
Authors
Naftali T, Bar-Lev Schleider L, Almog S et al.
DOI 10.1093/ecco-jcc/jjab069↗
Design: RCT (double-blind, placebo-controlled)
Share
Indication
Further studies on Crohn Disease
All studies →
S Mack et al. · 2019 · Gastroenterology
73 citations
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.
Unclear Systematic Review

Canadian Association of Gastroenterology Clinical Practice Guideline für pädiatrischen Morbus Crohn; 25 Statements nach GRADE-Methodik. Empfiehlt gegen Cannabis in jeder Rolle bei pädiatrischem Morbus Crohn. Systematische Evidenzbewertung durch iterativen Konsensusprozess.

10.1053/j.gastro.2019.03.022 View study →
A Abrams et al. · 2018 · European Journal of Internal Medicine
294 citations
The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report
Mixed Narrative Review

Update des National Academies of Sciences-Berichts zu therapeutischen Cannabis-Effekten (Abrams 2018); konsolidiert Evidenz für chronischen Schmerz, MS-Spastik, Chemotherapie-induzierte Übelkeit; für Morbus Crohn wird limitierte Evidenz für symptomatische Linderung bei fehlender antiinflammatorischer Wirkung zusammengefasst.

10.1016/j.ejim.2018.01.003 View study →
A Langhorst et al. · 2015 · Journal of Crohn's and Colitis
198 citations
Systematic Review of Complementary and Alternative Medicine Treatments in Inflammatory Bowel Diseases
Mixed Systematic Review

Systematische Review zu Komplementär- und Alternativmedizin bei IBD (Morbus Crohn und Colitis ulcerosa); k=39 Studien (26 RCTs + 3 CTs zu Phytotherapeutika, 7 RCTs zu Mind/Body-Interventionen, 2 RCTs zu Akupunktur, 1 RCT zu Trichuris suis). Evaluierte u.a. Cannabis als Phytotherapeutikum. Beste Evidenz für Plantago ovata und Curcumin bei UC-Erhaltungstherapie, Wermut bei CD, Mind/Body-Therapie bei UC, Akupunktur bei UC und CD. Heterogene methodische Qualität (Cochrane Risk of Bias).

10.1093/ecco-jcc/jju007 View study →

The impediment to action advances action. — Marcus Aurelius